Literature DB >> 20207564

Brain imaging in urea cycle disorders.

Andrea Gropman1.   

Abstract

Urea cycle disorders (UCD) represent a group of rare inborn errors of metabolism that carry a high risk of mortality and neurological morbidity resulting from the effects of accumulation of ammonia and other biochemical intermediates. These disorders result from single gene defects involved in the detoxification pathway of ammonia to urea. UCD include deficiencies in any of the six enzymes and two membrane transporters involved in urea biosynthesis. It has previously been reported that approximately half of infants who present with hyperammonemic coma in the newborn period die of cerebral edema; and those who survive 3days or more of coma invariably have intellectual disability [1]. In children with partial defects there is an association between the number and severity of recurrent hyperammonemic (HA) episodes (i.e. with or without coma) and subsequent cognitive and neurologic deficits [2]. However, the effects of milder or subclinical HA episodes on the brain are largely unknown. This review discusses the results of neuroimaging studies performed as part of the NIH funded Rare Diseases Clinical Research Center in Urea Cycle Disorders and focuses on biomarkers of brain injury in ornithine transcarbamylase deficiency (OTCD). We used anatomic imaging, functional magnetic resonance imaging (fMRI), diffusion-tensor imaging (DTI), and (1)H/(13)C magnetic resonance spectroscopy (MRS) to study clinically stable adults with partial OTCD. This allowed us to determine alterations in brain biochemistry associated with changes in cell volume and osmolarity and permitted us to identify brain biomarkers of HA. We found that white matter tracts underlying specific pathways involved in working memory and executive function are altered in subjects with OTCD (as measured by DTI), including those heterozygous women who were previously considered asymptomatic. An understanding of the pathogenesis of brain injury in UCD is likely to advance our knowledge of more common disorders of liver dysfunction. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20207564      PMCID: PMC3258295          DOI: 10.1016/j.ymgme.2010.01.017

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  61 in total

1.  Neurological outcome of patients with ornithine carbamoyltransferase deficiency.

Authors:  P Nicolaides; D Liebsch; N Dale; J Leonard; R Surtees
Journal:  Arch Dis Child       Date:  2002-01       Impact factor: 3.791

2.  In vivo nitrogen metabolism in ornithine transcarbamylase deficiency.

Authors:  M Yudkoff; Y Daikhin; I Nissim; A Jawad; J Wilson; M Batshaw
Journal:  J Clin Invest       Date:  1996-11-01       Impact factor: 14.808

3.  Ornithine transcarbamylase deficiency with persistent abnormality in cerebral glutamate metabolism in adults.

Authors:  Andrea L Gropman; Napapon Sailasuta; Kent C Harris; Osama Abulseoud; Brian D Ross
Journal:  Radiology       Date:  2009-06-30       Impact factor: 11.105

Review 4.  Cognitive development in children with inborn errors of urea synthesis.

Authors:  M Msall; P S Monahan; N Chapanis; M L Batshaw
Journal:  Acta Paediatr Jpn       Date:  1988-08

5.  [1-13C]glucose MRS in chronic hepatic encephalopathy in man.

Authors:  S Blüml; A Moreno-Torres; B D Ross
Journal:  Magn Reson Med       Date:  2001-06       Impact factor: 4.668

6.  1H MRS identifies symptomatic and asymptomatic subjects with partial ornithine transcarbamylase deficiency.

Authors:  A L Gropman; S T Fricke; R R Seltzer; A Hailu; A Adeyemo; A Sawyer; J van Meter; W D Gaillard; R McCarter; M Tuchman; M Batshaw
Journal:  Mol Genet Metab       Date:  2008-07-26       Impact factor: 4.797

7.  Glutamine synthetase inhibition prevents cerebral oedema during hyperammonemia.

Authors:  H Takahashi; R C Koehler; S W Brusilow; R J Traystman
Journal:  Acta Neurochir Suppl (Wien)       Date:  1990

8.  Survival after treatment with phenylacetate and benzoate for urea-cycle disorders.

Authors:  Gregory M Enns; Susan A Berry; Gerard T Berry; William J Rhead; Saul W Brusilow; Ada Hamosh
Journal:  N Engl J Med       Date:  2007-05-31       Impact factor: 91.245

9.  Longitudinal changes in patients with traumatic brain injury assessed with diffusion-tensor and volumetric imaging.

Authors:  Barbara B Bendlin; Michele L Ries; Mariana Lazar; Andrew L Alexander; Robert J Dempsey; Howard A Rowley; Jack E Sherman; Sterling C Johnson
Journal:  Neuroimage       Date:  2008-05-07       Impact factor: 6.556

Review 10.  Mechanisms of ammonia-induced astrocyte swelling.

Authors:  M D Norenberg; K V Rama Rao; A R Jayakumar
Journal:  Metab Brain Dis       Date:  2005-12       Impact factor: 3.655

View more
  28 in total

1.  The phenotypic spectrum of organic acidurias and urea cycle disorders. Part 2: the evolving clinical phenotype.

Authors:  Stefan Kölker; Vassili Valayannopoulos; Alberto B Burlina; Jolanta Sykut-Cegielska; Frits A Wijburg; Elisa Leão Teles; Jiri Zeman; Carlo Dionisi-Vici; Ivo Barić; Daniela Karall; Jean-Baptiste Arnoux; Paula Avram; Matthias R Baumgartner; Javier Blasco-Alonso; S P Nikolas Boy; Marlene Bøgehus Rasmussen; Peter Burgard; Brigitte Chabrol; Anupam Chakrapani; Kimberly Chapman; Elisenda Cortès I Saladelafont; Maria L Couce; Linda de Meirleir; Dries Dobbelaere; Francesca Furlan; Florian Gleich; Maria Julieta González; Wanda Gradowska; Stephanie Grünewald; Tomas Honzik; Friederike Hörster; Hariklea Ioannou; Anil Jalan; Johannes Häberle; Gisela Haege; Eveline Langereis; Pascale de Lonlay; Diego Martinelli; Shirou Matsumoto; Chris Mühlhausen; Elaine Murphy; Hélène Ogier de Baulny; Carlos Ortez; Consuelo C Pedrón; Guillem Pintos-Morell; Luis Pena-Quintana; Danijela Petković Ramadža; Esmeralda Rodrigues; Sabine Scholl-Bürgi; Etienne Sokal; Marshall L Summar; Nicholas Thompson; Roshni Vara; Inmaculada Vives Pinera; John H Walter; Monique Williams; Allan M Lund; Angeles Garcia-Cazorla; Angeles Garcia Cazorla
Journal:  J Inherit Metab Dis       Date:  2015-04-15       Impact factor: 4.982

Review 2.  Urea cycle disorder misdiagnosed as multiple sclerosis: a case report and review of the literature.

Authors:  Hussein Algahtani; Seham Alameer; Yousef Marzouk; Bader Shirah
Journal:  Neuroradiol J       Date:  2017-06-21

3.  Urea cycle disorders: brain MRI and neurological outcome.

Authors:  William R Bireley; Johan L K Van Hove; Renata C Gallagher; Laura Z Fenton
Journal:  Pediatr Radiol       Date:  2011-10-12

4.  Ornithine transcarbamylase deficiency that developed at the age of 19 years with acute brain edema.

Authors:  Hidenori Mitani; Toshiaki Mochizuki; Norio Otani; Hiroyuki Tanaka; Shinichi Ishimatsu
Journal:  Acute Med Surg       Date:  2016-05-13

Review 5.  Clinical practice: the management of hyperammonemia.

Authors:  Johannes Häberle
Journal:  Eur J Pediatr       Date:  2010-12-17       Impact factor: 3.183

Review 6.  Recurrent encephalopathy: NAGS (N-acetylglutamate synthase) deficiency in adults.

Authors:  A Cartagena; A N Prasad; C A Rupar; M Strong; M Tuchman; N Ah Mew; C Prasad
Journal:  Can J Neurol Sci       Date:  2013-01       Impact factor: 2.104

Review 7.  In Vivo NMR Studies of the Brain with Hereditary or Acquired Metabolic Disorders.

Authors:  Erica B Sherry; Phil Lee; In-Young Choi
Journal:  Neurochem Res       Date:  2015-11-26       Impact factor: 3.996

Review 8.  The neuropsychiatry of inborn errors of metabolism.

Authors:  Mark Walterfang; Olivier Bonnot; Ramon Mocellin; Dennis Velakoulis
Journal:  J Inherit Metab Dis       Date:  2013-05-23       Impact factor: 4.982

Review 9.  Bilateral symmetrical basal ganglia and thalamic lesions in children: an update (2015).

Authors:  Giulio Zuccoli; Michael Paul Yannes; Raffaele Nardone; Ariel Bailey; Amy Goldstein
Journal:  Neuroradiology       Date:  2015-07-31       Impact factor: 2.804

Review 10.  Ammonia toxicity to the brain.

Authors:  Olivier Braissant; Valérie A McLin; Cristina Cudalbu
Journal:  J Inherit Metab Dis       Date:  2012-10-30       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.